Summary
Functional genomics resources are critical for interpreting human genetic studies, however they are predominantly from European-ancestry individuals. Here we present the Southern African Blood Regulatory (SABR) resource, a map of blood regulatory variation that includes three South Eastern Bantu-speaking groups. Using paired whole genome and blood transcriptome data from over 600 individuals, we map the genetic architecture of 40 blood cell traits derived from deconvolution analysis, as well as expression, splice, and cell type interaction quantitative trait loci. We comprehensively compare SABR to the Genotype Expression (GTEx) Project and characterize the thousands of African-enriched and African-specific regulatory variants mapped. Finally, we demonstrate the increased utility of SABR for interpreting African association studies by identifying putatively causal genes and molecular mechanisms through colocalization analysis of 83 blood-relevant traits from the PAN-UK Biobank. Importantly, we make full SABR summary statistics publicly available to support the African genomics community.
Competing Interest Statement
S.E.C., A.K.E, M.K, O.G., M.H., S.L.V.B., E.B., S.K., K.N., K.A.W., L.Y.A., were or are employees and/or equity owners at Variant Bio.
Funding Statement
The AWI-Gen Collaborative Centre that contributed foundational data for this study was funded by the National Institutes of Health (NIH) (award number U54HG006938) and the South African Department of Science and Innovation (award number DST/CON 0056/2014). The MRC/Wits Rural Public Health and Health Transitions Research Unit and Agincourt Health and Socio-Demographic Surveillance System, a node of the South African Population Research Infrastructure Network (SAPRIN), is supported by the Department of Science and Innovation, the University of the Witwatersrand, and the Medical Research Council, South Africa, and previously the Wellcome Trust, UK (grants 058893/Z/99/A; 069683/Z/02/Z; 085477/Z/08/Z; 085477/B/08/Z). M.R. is a South Africa Research Chair on Genomics and Bioinformatics of African Populations supported by the National Research Foundation of South Africa (Ref Number 89646). This work represents the views of the authors and does not necessarily reflect the views of the funders. It has enabled securing additional NIH funding (award number U01HL172182) for a project led by A.C. and titled 'Integrated modeLs for Early Risk-prediction in Africa (ILERA)'.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Using established community engagement and information dissemination channels, we engaged community stakeholders through in person meetings (when possible) at each Study Centre before participants were approached and informed consent sought. In the semi-rural rapidly transitioning rural context of Agincourt (Mpumalanga) and the peri-urban environment of DIMAMO (Limpopo) Study Centres, we met with community advisory boards of the HDSS Centres in May 2021 to explain what the study was about, how the selection and consenting process would proceed, and what benefit sharing would entail for their communities. It was an opportunity to hear their views, respond to their questions and concerns, and to adjust our processes in line with their suggestions. We also received feedback on the following issues: (a) How they felt about the project in general and whether they considered that it would be valuable for their communities to participate; (b) If they felt comfortable with how their data would be used and what would happen to the data, for example data sharing with the wider scientific community. It was stressed that no individually identifying data would be shared; (c) How they felt about providing biological samples and disposal and/or repatriation of the samples. In the urban Soweto study setting, given that this was during the COVID-19 pandemic, our partners interacted with the municipal ward-councilors to explain the study to them and then proceeded with recruitment in line with the processes of the Developmental Pathways for Health Research Unit. Recruitment started in June 2021 and was completed by November 2021. All three research centers were mindful of taking precautionary measures related to possible infection during the pandemic and used masks and sanitisers during all interactions, with frequent decontamination of transport vehicles (if they were transporting participants) and recruitment study rooms. No adverse events were reported during the recruitment phase. Once participant recruitment was completed, the community benefit sharing process was put in place and competed by November 2022. This process will be described elsewhere and was in line with the processes developed by Variant Bio 8. Ethical approval for this study was provided by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M210214), University of Limpopo Research Ethics Committee (TREC/199/201:IR) and the protocol was reviewed by the Variant Bio ethics committee. Individual participants gave voluntary informed consent to participate in the study before taking part.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
